AUSTIN, Oct. 12, 2020 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company developing simple, easy to use, cost effective blood tests
to help diagnose a range of cancers and other diseases in both
humans and animals, will present two abstracts relating to its
first product, the Nu.Q™ Vet Cancer Screening Test, at the 2020
Veterinary Cancer Society (VCS) Virtual Annual Conference, which
takes place from Thursday, October 15
through Saturday, October 17.
The first abstract "Characterizing Circulating Nucleosomes in
the Plasma of Dogs with Lymphoma," will be presented on
Friday, October 16 at 1:30 p.m. Eastern Time.
The second abstract, "Characterizing Circulating Nucleosomes in
the Plasma of Dogs with Hemangiosarcoma," will be presented on
Saturday, October 17 at 11:15 a.m. Eastern Time.
Volition will release further details regarding these abstracts
on Friday, October 16.
Volition is proud to sponsor the 2020 VCS Virtual Annual
Conference and will be providing more information about the
veterinary applications of its Nucleosomics™ technology for early
detection of cancer and other diseases from a virtual exhibition
booth at the event.
To register for this conference click here.
The abstracts will be posted to the Volition website on
Monday October 19.
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of NucleosomicsTM, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily
focused on human diagnostics but also has a subsidiary focused on
animal diagnostics.
Volition's research and development activities are centered in
Belgium, with additional offices
in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
Nucleosomics™ and Nu.Q™ and their respective logos are
trademarks of Volition and its subsidiaries.
For more information about Volition, visit Volition's website
(http://www.volition.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn:
https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Pegasus
jen.lewis@thisispegasus.co.uk
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the timing of the commercial launch of Volition's test platforms
for early detection of cancer and other diseases. Volition's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic or prognostic products, it may be
unable to execute its plan of operations. Other risks and
uncertainties include Volition's failure to obtain necessary
regulatory clearances or approvals to distribute and market future
products; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic or
prognostic products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
market and its rapid technological change; downturns in domestic
and foreign economies; and other risks identified in Volition's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
View original
content:http://www.prnewswire.com/news-releases/volition-veterinary-diagnostics-development-llc-to-present-product-data-regarding-its-nuq-vet-cancer-screening-test-at-the-2020-vcs-virtual-annual-conference-301150057.html
SOURCE VolitionRx Ltd